ТОО "AVA MED & PHARM"
This is a company preview
Unlock the full report for 1 check — contacts, bank accounts, court cases, government contracts, arrests, licenses and PDF export.
Risks
0/17Комитет государственных доходов · Государственные закупки РК · АО ФНБ «Самрук-Казына» · АОО «НИШ»This assessment is informational and analytical only, based on our internal methodology and open sources; it is not an official government conclusion or a guarantee of reliability.
Procurement signals
Arrests & encumbrances
Enforcement proceedings
Certificates
Licenses and permits
Summary
Министерство юстиции РКHas changed
Activities
86109 Деятельность других лечебных учреждений, имеющих стационары
Деятельность других лечебных учреждений, имеющих стационары
Contacts
Change history
Financial statements
PremiumPublic contracts
What it sells and where
Samruk-Kazyna procurement
Tender bids
Procurement as a customer
Assets
Bank accounts
Leadership
1- ТА
Төлепберген Азамат Нұрланұлы
Director
Founders
Accreditations
Employees
Affiliated companies
PremiumDirector's involvement in other legal entities
Branches
Company networks
PremiumSimilar companies
Media mentions
Company summary
ТОО "AVA MED & PHARM" (BIN 241240003042): Active legal entity, Turkestan Region, registered in 2024, 2 years on the market. Main activity: healthcare. Enterprise category: small enterprise, up to 5 employees. No risk indicators for «AVA MED & PHARM» were found in open registries. Latest registry change: change in headcount, November 1, 2025. Founders: 1. Director on record: Төлепберген Азамат Нұрланұлы. Registry snapshot dated June 11, 2026.
Data sources and disclaimer
Sources: Министерство юстиции РК, Комитет государственных доходов МФ РК, Верховный Суд РК, Портал государственных закупок РК, АО «Самрук-Казына», Бюро национальной статистики РК, Портал электронного лицензирования. Data is collected automatically and may lag behind primary sources; the absence of a record does not guarantee the absence of the fact. This is reference information and does not replace an official extract. Methodology: SafeDeal editorial policy.